Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Jacqueline A. Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce & Onur Baser. (2017) Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Current Medical Research and Opinion 33:4, pages 723-731.
Read now
Read now
Kruti Joshi, Xiaoyun Pan, Rosa Wang, Erru Yang & Carmela Benson. (2016) Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Current Medical Research and Opinion 32:11, pages 1873-1881.
Read now
Read now
Fan Zhang, Tianmei Si, Chiun-Fang Chiou, Anthony WF Harris, Chang Yoon Kim, Padmashree Jahagirdar & Steve Ascher. (2015) Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 657-668.
Read now
Read now
Onur Baser, Lin Xie, Jacqueline Pesa & Mike Durkin. (2015) Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. Journal of Medical Economics 18:5, pages 357-365.
Read now
Read now
John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland. (2015) Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics 18:2, pages 145-154.
Read now
Read now
Marie-Hélène Lafeuille, Jason Dean, Valerie Carter, Mei Sheng Duh, John Fastenau, Riad Dirani & Patrick Lefebvre. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current Medical Research and Opinion 30:8, pages 1643-1655.
Read now
Read now
Thomas R. Einarson & Michiel E. H. Hemels. (2013) Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics 16:11, pages 1267-1274.
Read now
Read now
John M. Kane, Raymond Sanchez, Joan Zhao, Anna R. Duca, Brian R. Johnson, Robert D. McQuade, Anna Eramo, Ross A. Baker & Timothy Peters-Strickland. (2013) Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics 16:7, pages 917-925.
Read now
Read now
Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin, Ross A. Baker & Craig Karson. (2013) Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. Journal of Medical Economics 16:4, pages 522-528.
Read now
Read now
L Annemans, I Eijgelshoven, A Smet, A Jacobs & G Bergman. (2012) THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL. Acta Clinica Belgica 67:2, pages 108-119.
Read now
Read now
Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries, Robert R Conley & Kory J Schuh. (2011) Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. ClinicoEconomics and Outcomes Research 3, pages 9-14.
Read now
Read now
Chris M. Kozma, Terra Slaton, Riad Dirani, John Fastenau, Srihari Gopal & David Hough. (2011) Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Current Medical Research and Opinion 27:8, pages 1603-1611.
Read now
Read now
Articles from other publishers (11)
Tiffany Cristarella, Genaro Castillon, Jean‐François Nepveu & Yola Moride. (2022) Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Dominic Pilon, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Bruno Emond, Patrick Lefebvre & Kruti Joshi. (2017) Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clinical Therapeutics 39:10, pages 1972-1985.e2.
Crossref
Crossref
Fabienne Chou, Earle Reome & Patricia Davis. (2016) Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder. Mental Health Clinician 6:5, pages 254-259.
Crossref
Crossref
Bunta Yoshimura, Ikuta Shinkawa & Akiko Konishi. (2015) Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan. Asian Journal of Psychiatry 14, pages 67-68.
Crossref
Crossref
Marie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Fortier, Erik Muser, John Fasteneau, Mei Sheng Duh & Patrick Lefebvre. (2015) Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. American Journal of Health-System Pharmacy 72:5, pages 378-389.
Crossref
Crossref
Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin & Craig Karson. (2014) Hospitalization Resource Utilization and Costs Among Medicaid Insured Patients With Schizophrenia With Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy. Journal of Clinical Psychopharmacology 34:1, pages 30-35.
Crossref
Crossref
Marie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, Christian Frois, John Fastenau & Mei Sheng Duh. (2013) Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13:1.
Crossref
Crossref
Steve Offord, Jay Lin, Dario Mirski & Bruce Wong. (2013) Impact of Early Nonadherence to Oral Antipsychotics on Clinical and Economic Outcomes Among Patients with Schizophrenia. Advances in Therapy 30:3, pages 286-297.
Crossref
Crossref
Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao & Wayne Macfadden. (2011) Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry 11:1.
Crossref
Crossref
José M Olivares, Beatriz Pinal & Carmen Cinos. (2011) Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry 1:3, pages 275-289.
Crossref
Crossref
X. S. Ren, C. Crivera, M. Sikirica, R. Dirani, S. Qian & L. E. Kazis. (2011) Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Journal of Clinical Pharmacy and Therapeutics 36:3, pages 383-389.
Crossref
Crossref